WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018026249) ANTIBODY AGAINST PROGRAMMED DEATH-LIGAND 1 (PD-L1), AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/026249    International Application No.:    PCT/KR2017/008495
Publication Date: 08.02.2018 International Filing Date: 07.08.2017
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61K 39/00 (2006.01)
Applicants: Y-BIOLOGICS INC. [KR/KR]; No. 306 11-3, Techno 1-ro Yuseong-gu Daejeon 34015 (KR)
Inventors: PARK, Jae Eun; (KR).
CHOI, Soo A; (KR).
LEE, Jisu; (KR).
LEE, Hyun Mi; (KR).
LEE, Si Hyung; (KR).
BAEK, Gi Sun; (KR).
KIM, Yeung Chul; (KR).
PARK, Bum-chan; (KR).
LIM, Jung Chae; (KR).
CHO, Young-Gyu; (KR).
PARK, Young Woo; (KR)
Agent: LEE, Cheo Young; (KR).
CHANG, Je Hwan; (KR)
Priority Data:
10-2016-0100211 05.08.2016 KR
10-2017-0099673 07.08.2017 KR
Title (EN) ANTIBODY AGAINST PROGRAMMED DEATH-LIGAND 1 (PD-L1), AND USE THEREOF
(FR) ANTICORPS DIRIGÉ CONTRE LE LIGAND 1 DE MORT PROGRAMMÉE (PD-L1) ET SON UTILISATION
(KO) 프로그램화된 세포 사멸 단백질 리간드-1 (PD-L1)에 대한 항체 및 이의 용도
Abstract: front page image
(EN)The present invention relates to an antibody against programmed death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid for coding same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, and a composition, comprising same, for preventing or treating a cancer or an infectious disease.
(FR)La présente invention concerne un anticorps dirigé contre le ligand 1 de mort programmée (PD-L1) ou un fragment de liaison à l'antigène de celui-ci, un acide nucléique pour le codage de celui-ci, un vecteur comprenant l'acide nucléique, une cellule transformée avec le vecteur, un procédé de préparation de l'anticorps ou du fragment de liaison à l'antigène de celui-ci, et une composition le comprenant, pour la prévention ou le traitement d'un cancer ou d'une maladie infectieuse.
(KO)본 발명은 PD-L1(Programmed death-ligand 1)에 대한 항체 또는 이의 항원 결합 단편, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 그의 항원 결합 단편의 제조방법 및 이를 포함하는 암 또는 감염 질환의 예방 또는 치료용 조성물에 관한 것이다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)